Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Net Margin (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Net Margin for 7 consecutive years, with 125.09% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 438103.0% to 125.09% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 144.39% through Dec 2025, up 9705.0% year-over-year, with the annual reading at 144.39% for FY2025, 9705.0% up from the prior year.
  • Net Margin hit 125.09% in Q4 2025 for BridgeBio Pharma, up from 151.4% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 13.36% in Q2 2022 to a low of 40632.84% in Q3 2022.
  • Historically, Net Margin has averaged 7492.05% across 5 years, with a median of 4416.33% in 2023.
  • Biggest YoY gain for Net Margin was 9687331bps in 2021; the steepest drop was -3758901bps in 2021.
  • Year by year, Net Margin stood at 1471.77% in 2021, then plummeted by -400bps to 7357.81% in 2022, then plummeted by -31bps to 9635.99% in 2023, then soared by 53bps to 4506.12% in 2024, then soared by 97bps to 125.09% in 2025.
  • Business Quant data shows Net Margin for BBIO at 125.09% in Q4 2025, 151.4% in Q3 2025, and 164.52% in Q2 2025.